Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LXI-15028 vs Esomeprazole for Erosive Esophagitis in Chinese Patients
NCT03615677Phase 3Completed
- Sponsor
- Shandong Luoxin Pharmaceutical
- Start
- Oct 2018
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tegoprazan in erosive esophagitis (EE) (2 arms), sponsored by Shandong Luoxin Pharmaceutical. Primary endpoint: Cumulative endoscopic healing rate at 8 weeks. Started Oct 2018; status: completed.
02
Drugs
tegoprazan
03
Conditions
erosive esophagitis (EE)
Beyond the preview
Go deeper on NCT03615677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03615677.